Literature DB >> 3876404

Anticlonotypic monoclonal antibodies induce proliferation of clonotype-positive T cells in peripheral blood human T lymphocytes. Evidence for a phenotypic (T4/T8) heterogeneity of the clonotype-positive proliferating cells.

A Moretta, G Pantaleo, M Lopez-Botet, M C Mingari, L Moretta.   

Abstract

Three previously selected monoclonal antibodies (mAb) directed against the clonotypic structure of a variant (termed JA3) of the interleukin 2 (IL-2)-producing Jurkat leukemia cell line (anti-JTi1-3 mAb) were found to induce an adherent cell-dependent proliferation of peripheral blood T cells in 20 different donors. Unlike the early cell proliferation induced by anti-T3 mAb, anti-JTi mAb-induced proliferation was detectable at day 5-6 of culture and reached peak levels at day 7-9. Less than 1% JTi+ cells were consistently detected in the starting peripheral blood lymphocytes or in control cultures in which cells were stimulated with anti-T3, phytohemagglutinin, or allogeneic cells. However, JTi+ cells were found in increasing proportions after culture with anti-JTi mAb and they were mostly represented by large blast cells expressing either the T4 or the T8 antigen, together with typical activation antigens including HLA-DR, IL-2 receptor, and 4F2. Immunoprecipitation experiments and sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that anti-JTi-reactive molecules present on antibody-stimulated lymphocytes or on JA3 cells were similar, disulphide-linked heterodimeric structures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876404      PMCID: PMC2187855          DOI: 10.1084/jem.162.4.1393

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions.

Authors:  S C Meuer; S F Schlossman; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

2.  Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells.

Authors:  M C Mingari; F Gerosa; G Carra; R S Accolla; A Moretta; R H Zubler; T A Waldmann; L Moretta
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

3.  Selection and characterization of monoclonal antibodies to the idiotype-like structure of an interleukin-2-producing human leukemia T-cell line.

Authors:  A Moretta; G Pantaleo; M Lopez-Botet; L Moretta
Journal:  Int J Cancer       Date:  1985-08-15       Impact factor: 7.396

4.  Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones.

Authors:  S C Meuer; J C Hodgdon; R E Hussey; J P Protentis; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

5.  Stimulation of a subset of normal resting T lymphocytes by a monoclonal antibody to a crossreactive determinant of the human T cell antigen receptor.

Authors:  R D Bigler; D N Posnett; N Chiorazzi
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

6.  Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor complex.

Authors:  A Moretta; G Pantaleo; M Lopez-Botet; L Moretta
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

7.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

8.  Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations.

Authors:  A Moretta; G Pantaleo; L Moretta; M C Mingari; J C Cerottini
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

  8 in total
  6 in total

1.  Preparation of anti-T idiotype monoclonal antibody reacting with human T leukaemic cell lines and with a small percentage of peripheral T lymphocytes.

Authors:  T Takahashi; K Imai; T Sugiyama; T Sasaki; A Yachi
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activation.

Authors:  A Moretta; A Poggi; D Olive; C Bottino; C Fortis; G Pantaleo; L Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

3.  Bacterial toxins affect early events of T lymphocyte activation.

Authors:  S J Stewart; V Prpic; J A Johns; F S Powers; S E Graber; J T Forbes; J H Exton
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

4.  Perturbation of the human T-cell antigen receptor-T3 complex leads to the production of inositol tetrakisphosphate: evidence for conversion from inositol trisphosphate.

Authors:  S J Stewart; V Prpic; F S Powers; S B Bocckino; R E Isaacks; J H Exton
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.

Authors:  A Moretta; A Poggi; D Pende; G Tripodi; A M Orengo; N Pella; R Augugliaro; C Bottino; E Ciccone; L Moretta
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

6.  P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities.

Authors:  A Moretta; M Vitale; C Bottino; A M Orengo; L Morelli; R Augugliaro; M Barbaresi; E Ciccone; L Moretta
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.